Early research shows results for ‘vaccine’
Posted: Wed Feb 18, 2015 3:54 am
In April 2010, sipuleucel-T (Provenge) became the first dendritic cell vaccine in cancer treatment to be approved by the US Food and Drug Administration (FDA), and the agent is now used in the treatment of metastatic castration-resistant prostate cancer. Insights gleaned from this research are now being applied in the study of a potential vaccine for multiple sclerosis (MS) treatment and prevention.
“We discovered DC-ASGPR, one of the receptors expressed on human dendritic cells, has novel functions to promote antigen-specific regulatory T cells that can efficiently suppress inflammatory responses,” said principal investigator SangKon Oh, PhD, from the Baylor Institute for Immunology Research, in a press release. “This prompted us to test our discovery in autoimmune diseases where antigens are known..........” Read More - http://www.ms-uk.org/vaccinations
“We discovered DC-ASGPR, one of the receptors expressed on human dendritic cells, has novel functions to promote antigen-specific regulatory T cells that can efficiently suppress inflammatory responses,” said principal investigator SangKon Oh, PhD, from the Baylor Institute for Immunology Research, in a press release. “This prompted us to test our discovery in autoimmune diseases where antigens are known..........” Read More - http://www.ms-uk.org/vaccinations